Healthcare conferences provide unique opportunities to gain first-hand insights from otherwise inactive HCPs on social media. Before, during, and immediately after large congresses, HCPs share their thoughts on the results of clinical trials, product usage, and more on Twitter and other social channels.
Using social media listening technology, AplusA analyze the conversations surrounding large healthcare events. We use our expertise in traditional analysis, to share relevant insights on products, topics, and, trends to healthcare marketers.
What types of information about real life healthcare industry events is it possible to gain from social media research?
Combining social media listening software with our expertise in traditional market research we identified several different types of information around ESMO 2019 relevant to healthcare marketers. By analysing the conversations happening around the event, we are able to gain an overview of the most frequently discussed topics.
Share of voice
Social media listening software enables us to discover the share of voice around a brand, product, therapy area, or topic at a conference.
For example, at ESMO 2019, the top three cancers discussed on social media during the conference were
"Promising results of #olarib in #ProstateCancer with #HRR mutations! Don't forget that #BRCA2 & #gene #mutations can be #germline with #family implications."
"Olaparib, a new SOC in mCRPC with at least BRCA2 mutations? Is this the end of the sequencing therapy age in prostate cancer? #ESMO19 #Barcelona
- Dr. Sergio Vasquez - Oncologist, Head of Oncology at Lucus Augusti Hospital
"#esmo19 olaparib + bevacizumab + chemo should be a new standard of care in the first line treatment of ovarian cancer
Dr. Shannon Westin - Gynecologist Oncologist
Sentiment analysis gives an indication of whether the conversations surrounding an event, topic, or product are positive, negative, or neutral. In the case of ESMO 2019, the analysis we conducted showed that the sentiment was:
Most mentioned clinical trials
Which trials are at the forefront of conversation at the biggest healthcare conferences? At last year's ESMO, these were the three most mentioned:
PROfound trial - phase III trial of olaparib vs enzalutamide or abiraterone for metastatic castration resistant prostate cancer.
PAOLA trial - phase III trial of laparib plus bevacizumab as maintenance therapy in patients with newly diagnosed cancer
Mediola trial - phase I/II trial of olaparib + durvalumab in patients with advanced solid tumors
Social media listening in the onco-hematology market
For more in-depth examples of social media listening in the context of the onco-hematology market, download our latest eBook on the DLBCL market, including patient journey insights from social media analysis.
For more information on our social media listening services, please contact us here.